Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells

  • Peiju Qiu1,
  • Siwen Wang1,
  • Ming Liu1,
  • He Ma1,
  • Xuan Zeng1,
  • Meng Zhang1,
  • Lingling Xu1,
  • Yidi Cui1,
  • Huixin Xu1,
  • Yang Tang1,
  • Yanli He1 and
  • Lijuan Zhang1, 2Email author
BMC Cancer201717:55

https://doi.org/10.1186/s12885-016-3039-x

Received: 23 August 2016

Accepted: 23 December 2016

Published: 13 January 2017

Abstract

Background

Norcantharidin (NCTD) is a Chinese FDA approved, chemically synthesized drug for cancer treatment. The effect of NCTD on signaling proteins of EGFR and c-Met was systematically elucidated in current study.

Methods

Two human colon cancer cell lines, HCT116 and HT29, were used as model systems to investigate the anti-cancer molecular mechanism of NCTD. Cell cycle arrest and early/late apoptosis were analyzed by flow cytometry. The levels of EGFR, phospho-EGFR, c-Met, phospho-c-Met and other related proteins were quantified by western blot analysis.

Results

NCTD induced cell cycle arrest at G2/M phase in both cell lines. The early and late apoptosis was also observed. Further investigation indicated that NCTD suppressed not only the expression of the total EGFR and the phosphorylated EGFR but also the expression of the total c-Met and the phosphorylated c-Met in colon cancer cells. Moreover, EGFR expression could be mostly restored by co-treatment with MG132, a proteasome inhibitor. In addition, NCTD-induced cell death was comparable to that of the anti-cancer drug gefitinib, a tyrosine kinase inhibitor for EGFR, based on the immunoblot analysis of the expressed proteins after the drug treatment.

Conclusions

NCTD might be a useful and inexpensive drug candidate to substitute for gefitinib to serve the treatment needs of cancer patients.

Keywords

Norcantharidin Colon cancer Cell cycle Apoptosis EGFR c-Met

Background

Cantharidin (CTD) is isolated from Mylabris phalerata Pall, a valued traditional Chinese medicine in treating skin problems, such as furuncles and piles, for more than 2000 years in China. In recent years, CTD has been identified as the active compound in Mylabris phalerata Pall with anti-tumor activity [14]. However, it causes severe side effects in the urinary system both in animals and in human [5]. Norcantharidin (NCTD), which is chemically demethylated from CTD (Fig. 1), overcomes the urological toxicity while enhancing its anti-tumor activity [6]. Based on the cinical studies, NCTD has been approved by Chinese FDA for liver, esophageal, and gastric cancer treatment in China since 1996.
Fig. 1

The structure of norcantharidin (NCTD) and cantharidin (CTD)

Numerous studies have indicated that NCTD possessed the abilities to induce cell death for multiple types of cancer cells, for example, colorectal and lung cancer cells. The anti-cancer activity of NCTD relies on its ability in activation of the caspase signaling pathway that leads to apoptosis [7] accompanied with a decreased ratio of Bcl-2/Bax [8, 9], the changes in the expression of cell cycle-related proteins are co-related with cell cycle arrest [10], the interruption of DNA synthesis [11], inhibition of tumor invasion and metastasis [12, 13], MAPK activation, and protein kinase C pathway activation [14].

Colon cancer is the fourth most common cancer in the world found in both men and women. It is well known that two cell surface receptor tyrosine kinases, c-Met and EGFR, are co-present in 78% [15] to 80% [16, 17] in colon cancer cells. EGFR and c-Met corroborate the downstream signaling pathways in cancer cells in that c-Met and EGFR activate many of the same downstream signaling molecules. c-Met signaling is mainly responsible for cancer cell survival when EGFR inhibitors, such as gefitinib, are used during cancer treatment [18]. So far, few c-Met inhibitors or c-Met pathway antagonists have been developed into drugs. Even though several novel compounds are in clinical trials, their potential use might be limited by their potency, pharmacokinetic defect, and safety profile [19]. Therefore, it is highly desirable to find dual inhibitor for both EGFR and c-Met, especially from the existing drugs, to facilitate colon cancer treatment.

In current study, we demonstrated that NCTD suppressed the expressing level and phosphorylation of both c-Met and EGFR. Moreover, NCTD-induced cell death was comparable to that of the anti-cancer drug gefitinib, a tyrosine kinase inhibitor for EGFR, based on the immunoblot analysis of the expressed proteins after the treatment of NCTD.

Methods

Cell-related experiment and NCTD treatment

HT29 and HCT116, two human colon cancer cell lines, were obtained, maintained, and passaged using the identical protocol described in the published report [20]. NCTD was obtained from National Institutes for Food and Drug Control (Shandong, China). NCTD was dissolved in dimethylsulfoxide (DMSO) and the final concentration of DMSO used was 0.1% in culture media for all experiments.

Cell growth inhibition assay

HT29 and HCT116 cells suspended in complete media were seeded in 96-well plates (2000 cells/well). After growing for 24 h in incubator, media were aspirated and 0.2 mL complete media containing serial concentrations of NCTD were added to each well. After incubating the plate for 24, 48, or 72 h, 20 μL of resazurin (2 mg/mL dissolved in water, Sigma) was added to each well. The fluorescent signal was monitored using 544 nm excitation and 595 nm emission wavelengths by Spectramax M5 plate reader (Molecular Devices) after incubation at 37 °C for 16 h in the incubator. The number of living cells in each well was proportional to the relative fluorescence unit (RFU) measured by the assay [20].

Cell cycle analyses

HCT116 and HT29 cells were added in 6-well plates with 6 × 104 cells/well with 2 mL complte media per well. After incubation for 24 h, different concentrations of NCTD in 2 mL of complete media was added to treat cells. After 24 h incubation, the cell pellets were collected using the published protocol [20] and resuspended in 1 mL of 70% ethanol at 4 °C overnight. For analysis, the supernatant was removed by centrifuging at 1600 g for 1 min. The cell pellets were incubated with 0.5 mL PI/RNase Staining Buffer (BD Biosciences) for 15 min at room temperature. Single-cell suspension was generated by gentle pipetting. The cells was analyzed using Beckman cell analyzer FC500-mpl. Beckman CXP software and Multicycle software were used for data analysis.

Apoptosis assay

Annexin V/propidium iodide (PI) double staining assay (BD Biosciences, San Diego CA, USA) was used to quantify the apoptotic cells by following the manufacturer’s instruction [21]. Briefly, HCT116 and HT29 cells were treated with different concentration of NCTD in complete cell culture media for 24 h. After removing NCTD-containing media, cells were incubated in 100 μL buffer containing Annexin V and PI at room temperature for 15 min. Beckman cell analyzer FC500-mpl was then used to analyze the apoptotic cells.

Western blot analysis

HCT116 and HT29 cells were cultured in 10-cm dishes for 24 h before treated with different concentrations of NCTD or NCTD plus MG132 (Beyotime biotechnology, China). After being incubated with another 72 h, the cells were collected with cell-scrapers into 1.5 mL tube and put on ice for 30 min in whole cell lysis buffer (Cell Signaling Technology, USA) containing protease inhibitors. Proteins were quantified by BCA protein assay kit. Equal amount of proteins from different sample (50 μg) were resolved over 8 or 12% SDS-polyacrylamide gel by electrophoresis and then transferred to nitrocellulose membrane. The membranes were put in blocking buffer at room temperature for 2 h before appropriate primary antibody was added. The membrane was incubated in the presence of primary antibody at 4 °C overnight before the corresponding secondary antibodies were added. The membranes were then visualized by using Western Lightning. Antibodies for EGFR, Phospho-EGFR (Tyr1068), Her-2, Phospho-Her2/ErbB2 (Tyr1248), c-Met, Phospho-c-Met (Tyr1003), Caspase-3, Rb, β-Actin, PARP, CDK-2, CyclinD1, and Bax were purchased from Cell Signaling Technology (USA).

Results

NCTD inhibited HCT116 and HT29 cell proliferation

The inhibitory effects of NCTD on cell proliferation of HCT116 (Fig. 2a) and HT29 (Fig. 2b) were detected by the resazurin assay. As shown in Fig. 2, NCTD induced time- and concentration-dependent cell death in both HCT116 and HT29 cells. Clinically, NCTD (Mw 168) comes either as tablets to take by mouth (5-15 mg, 3 times a day) or to take by injections (10–20 mg/day). A patient generally has 4 to 5 l of blood. Therefore, the maximum concentrations of NCTD in patient’s blood should be around 4–5 μg/mL (24–30 μM). The data in Fig. 2 showed that 100 μM (16.8 μg/mL) NCTD induced >50% cell death in both cancer cell lines at all the time (24, 48, and 72 h) points tested. Based on the data, NCTD were further studied from 6.25 to 100 μM in both cancer cell lines for different types of tests.
Fig. 2

Effect of NCTD on cell viability. HCT116 (a) and HT29 (b) human colon cancer cells were seeded in 96-well plates with 2000 cells/well, respectively. After 24 h, cell culture media were replaced with 200 μL complete media containing serial concentrations of NCTD to treat the cells within the time of period indicated. The viable cells were measured by the fluorescent signal as described in the Material and Methods Section. The experiments were repeated for three times

NCTD suppressed the expression and activation of c-Met and EGFR in HCT116 and HT29 cells

To understand the NCTD-induced cytotoxicity, we tested the activation and expression of the EGFRs and c-Met after NCTD treatment. As shown in Fig. 3a, NCTD at 25 μM suppressed the phosphorylation of EGFR (Tyr1068) by 50%, however, NCTD moderately decreased the level of EGFR even up to 100 μM. Her-2 is another predominant member of EGFR family. Treatment of NCTD also significantly decreased the level of Her-2 and phosphor-Her-2 in dose-dependent manner. Importantly, NCTD substantially decreased expression of both phospho-c-Met and total c-Met. For example, NCTD at 6.25, 25, 100 μM decreased the level of phosphor-c-Met by 50, 60, 92% while inhibited the expression of total c-Met by 30, 50, 96%, respectively. Parallelly, HT29 responded to NCTD in the same trend, i.e., NCTD suppressed the activation of EGFR, Her-2 and c-Met in dose-dependent manner (Fig. 3b).
Fig. 3

Effects of NCTD on the expression and activation of EGFR and c-Met on HCT116 (a) and HT29 (b) human colon cancer cells. The cells were seeded in 10-cm dishes for 24 h, and then cells were treated with NCTD or gefitinib (c) at 6.25, 12.5, 25, 50, and 100 μM, respectively. After 72 h of incubation, cells were harvested for western blot analysis. Cells were treated with 100 μM of NCTD for the indicated periods after which the cells were collected and prepared for western blot analysis (d). HCT116 cells were treated with 50 μM NCTD or 50 μM NCTD plus 0.2 μM MG132 for 48 h (e). The expression of EGFR or β-Actin protein was detected by western blot analysis. The numbers underneath the blots represent band intensities (normalized to the loading controls, means of three independent experiments) measured by the Image J software. The standard deviations were all within ±15% of the means (data not shown). β-Actin was used as equal loading controls. The experiments were repeated for three times

To evaluate the potency of NCTD in killing colon cancer cells, we used gefinitib, the EGFR inhibitor, as the positive control. We compared the effect of gefinitib on attenuating the expression of the same group proteins, i.e., EGFR, Her-2 and c-Met, at two concentrations of 25 μM and 50 μM, respectively. Based on the protein band intensities, we found that NCTD exhibited stronger inhibitory effect on phosphorylation of c-Met, EGFR, and Her-2 at the concentration tested despite the expression of phosphor-Her-2 at 50 μM. Altogether, we concluded that NCTD was comparable to gefinitib in attenuating colon cancer cell growth (Fig. 3c).

In a time-dependent study, HCT116 cells were treated by NCTD at 100 μM for a period up to 72 h. The same group of proteins including c-Met, EGFR, Her-2, were analyzed again by western blot analysis. Decrease of total and phospho-c-Met, EGFR, Her-2 occurred in the 6 to 24 h and persisted for up to 72 h (Fig. 3d) by NCTD treatment.

The mechanisim of the downregulation of EGFR induced by NCTD in HCT116 cell was further invesitigated by co-treatment in combination with MG132, a proteasome inhibitor. As showed in Fig. 3e, NCTD induced 50% decrease in EGFR expression while NCTD plus MG132 induced 20% decrease in EGFR which indicated NCTD inhibited EGFR expression mainly via proteasome-mediated degradation.

G2/M cell cycle arrest induced by NCTD

To understand how NCTD induced cell death in both cell lines, flow cytometry assay was used to study the effect of NCTD on cell cycle after treating the cells with varied concentrations of NCTD. NCTD caused G2/M phase cell population accumulation in a dose-dependent manner in HCT116 cells compared to that of control (Fig. 4b), which was consistent with previous report [22]. For example, at the concentration of 12.5 and 50 μM, NCTD induced an increase in G2/M phase cell population by 2.2- to 4-fold, respectively. Similar results were observed in HT29 cell line when the concentration of NCTD was above 50 μM. Interestingly, the cell population of G2/M phase had no change when the NCTD concentrations were below 25 μM (Fig. 4c).
Fig. 4

Cell cycle distribution of HCT116 (a) and HT29 (b) human colon cancer cells after treatment with NCTD. The cells were seeded in 6-well plates for 24 h and then treated with NCTD in complete media. After 24 h treatment, cells were harvested and subjected to cell cycle analyses as described in Materials and Methods. All data represent mean ± SD. Statistical analysis were conducted among control and treated groups in G0/G1, S and G2/M phases separately. Statistical significance was determined by Student’s t test (p < 0.001). * represent significant difference in cell number in the control that received PBS versus those treated with the indicated concentration of NCTD. Each bar represents the average value ± S.D; n = 3

NCTD induced early/late apoptosis

We also measured the degree of apoptosis induced by NCTD. As shown in Fig. 5a, compared to the control, treating HCT116 cells with NCTD increased the percentage of early and late apoptotic cells significantly in a concentration-dependent manner (Fig. 5a). For example, NCTD at 100 μM increased early apoptotic cell population by 38.44-fold over the control cells, which was similar for HT29 cells (Fig. 5b).
Fig. 5

Effect of NCTD on apoptosis in HCT116 (a) and HT29 (b) cells. The cells were seeded in 6-well plates for 24 h, and then the cells were treated with serial concentrations of NCTD. After 48 h of treatment, cells were harvested and subject to apoptosis analyses as described in Materials and Methods. The experiments were repeated for three times. Statistical significance was determined by Student’s t test (p < 0.001). * represent significant difference in cell number in the control that received PBS versus those treated with the indicated concentration of NCTD. Each bar represents the average value ± S.D.; n = 3

NCTD affected cell cycle- and apoptosis-related proteins

How NCTD affected cell cycle- and apoptosis-related signaling proteins was tested over a range of concentrations from 6.25 to 100 μM in both cell lines for 72 h. At 25 μM concentration of NCTD, the level of cleaved PARP were increased significantly and the cleaved caspase-3 was also to show up (Fig. 6a). However, another apoptosis-related protein, Bax, barely changed under this concentration. Meanwhile, the decrease on several cell cycle-related proteins including CyclinD1, Rb, CDK-4 was observed after treatment with 12.5 to 100 μM of NCTD. In addition, similar trends were detected when HT29 cell line was used to perform the same test. In conclusion, NTCD affected both cell cycle- and apoptosis-related signaling proteins in a concentration-dependent manner (Fig. 6b).
Fig. 6

Effects of NCTD on the key proteins regulating cell cycle and apoptosis in HCT116 (a) and HT29 (b) human colon cancer cells. The cells were seeded in 10-cm dishes for 24 h and then treated with different concentrations of NCTD. After 72 h of incubation, cells were collected for western blot analysis as described in the Materials and Methods. The numbers underneath of the blots represent band intensity (normalized to β-Actin, means of three independent experiments) measured by Image J software. The standard deviations (all within ± 15% of the means) were not shown. β-Actin was served as an equal loading control. The experiments were repeated for three times

Disscussion

Accumulating evidences indicated that both c-Met and EGFR were overexpressed by 78 to 80% of colon cancers, which were associated with poor outcome. A cross-talk of c-Met and EGFR could modulate reciprocally and eventually determine the intensity of c-Met signaling pathway [18]. One of the major findings of our study was that the mechanism underlying the cell death induced by NCTD involved in suppressing the expression and phosphorylation of c-Met and EGFR. To our knowledge, this is the first demonstration that NCTD was a dual inhibitor for c-Met and EGFR and in human colon cancers.

Another interesting finding was that signaling network might also exist between c-Met and Her-2 in colon cancer cells where the level of the two proteins decreased with the increased concentration of NCTD. However, we could not draw a conclusion how c-Met affected the expression and activation of Her-2, such as by direct suppression or indirect regulation. Additional studies were necessary to reveal the potential mechanism how c-Met downregulated Her-2 expression in colon cancer cells line.

With the dramatic effects against lung cancer, gefitinib has been the most used small molecular EGFR inhibitor. To evaluate the potency of NCTD in killing colon cancer cells, gefitinib was used as the positive control in our study. Our data showed that NCTD was better at suppressing the phosphorylation of EGFR tested at 25 μM while gefinitib exhibited stronger inhibitory effect on the phosphorylation of Her-2 at 50 μM. Collectively, the data suggested that NCTD might have a different mechanism from gefitinib in killing colon cancer cells. Remarkably, although the two drugs exhibited comparative effect on attenuating the EGFR, Her-2, and c-Met, NCTD seemed to possess certain advantages over gefitinib including lower cost, better safety, and superior tolerance of NCTD [6] (Fig. 7).
Fig. 7

Proposed molecular mechanisms by which NCTD inhibited human colon cancer cell growth

Conclusions

In conclusion, NCTD suppressed the phosphorylation and expression of both EGFR and c-Met in HCT116 and HT29 human colon cancer cells. Our data provided novle molecular mechanism for further investigation if NCTD could serve as a dual inhibitor for EGFR/c-Met in terms of colon cancer treatment.

Abbreviations

CTD: 

Cantharidin

NCTD: 

Norcantharidin

PI: 

Propidium iodide

RFU: 

Relative fluorescence unit

Declarations

Acknowledgments

We thank Dr. Mingzhuang Zhu for helping us with the flow cytometry analysis.

Funding

This research was supported by Shandong Science and Technology Development Planning Project (Grant No.2014GGH215001), Ministry of Education New Teacher’s Fund(Grant No. 20130132120006). Natural Science Foundation of China (Grant No. 91129706 and 81672585), and NSFC-Shandong Joint Fund (U1406402).

Availability of data and materials

All data supporting the findings in this study are included within the manuscript and the supplementary figures.

Authors’ contributions

LZ, PQ designed the experiments. SW, PQ, ML, MZ, LX, YC, HM, YT, and YH performed the experiments. PQ, SW, XZ, HX analyzed data. LZ, PQ wrote the manuscript. LZ and PQ revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

There was no research involving human or animal subjects in the study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China
(2)
Institute of Cerebrovascular Diseases, Affiliated Hospital of Qingdao University

References

  1. Li CC, Yu FS, Fan MJ, Chen YY, Lien JC, Chou YC, Lu HF, Tang NY, Peng SF, Huang WW, Chung JG. Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivo. Environ Toxicol. 2016. doi:10.1002/tox.22273.Google Scholar
  2. Le AP, Zhang LL, Liu W, Shi YF. Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells. Oncol Rep. 2016;35:2970–6.PubMedGoogle Scholar
  3. Shen M, Wu MY, Chen LP, Zhi Q, Gong FR, Chen K, Li DM, Wu Y, Tao M, Li W. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Sci Rep. 2015;5:11836.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Hsiao YP, Tsai CH, Wu PP, Hsu SC, Liu HC, Huang YP, Yang JH, Chung JG. Cantharidin induces G2/M phase arrest by inhibition of Cdc25c and Cyclin A and triggers apoptosis through reactive oxygen species and the mitochondria-dependent pathways of A375.S2 human melanoma cells. Int J Oncol. 2014;45:2393–402.PubMedGoogle Scholar
  5. Cotovio P, Silva C, Guedes Marques M, Ferrer F, Costa F, Carreira A, Campos M. Acute kidney injury by cantharidin poisoning following a silly bet on an ugly beetle. Clin Kidney J. 2013;6:201–3.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Hsieh CH, Chao KS, Liao HF, Chen YJ. Norcantharidin, derivative of cantharidin, for cancer stem cells. Evid Based Complement Alternat Med. 2013;2013:838651.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, Hsu SL. Effect or mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer. 2002;100:158–65.View ArticlePubMedGoogle Scholar
  8. Yang PY, Chen MF, Tsai CH, Hu DN, Chang FR, Wu YC. Involvement of caspase and MAPK activities in norcantharidin-induced colorectal cancer cell apoptosis. Toxicol In Vitro. 2010;24:766–75.View ArticlePubMedGoogle Scholar
  9. Xie J, Zhang Y, Hu X, Lv R, Xiao D, Jiang L, Bao Q. Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer. Med Oncol. 2015;32:145.View ArticlePubMedGoogle Scholar
  10. Yang PY, Chen MF, Kao YH, Hu DN, Chang FR, Wu YC. Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. Toxicol In Vitro. 2011;25:699–707.View ArticlePubMedGoogle Scholar
  11. Chen S, Wan P, Ding W, Li F, He C, Chen P, Li H, Hu Z, Tan W, Li J. Norcantharidin inhibits DNA replication and induces mitotic catastrophe by degrading initiation protein Cdc6. Int J Mol Med. 2013;32:43–50.PubMedGoogle Scholar
  12. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, Liao HF. Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs. 2005;16:293–9.View ArticlePubMedGoogle Scholar
  13. Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci. 2005;85:642–51.View ArticleGoogle Scholar
  14. Shen B, He PJ, Shao CL. Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion. PLoS One. 2013;8:e84610.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3:S21–35.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998;37:285–9.View ArticlePubMedGoogle Scholar
  17. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21:105–15.View ArticlePubMedGoogle Scholar
  18. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Invest Drugs. 2008;17:999–1011.View ArticleGoogle Scholar
  20. Qiu P, Xu L, Gao L, Zhang M, Wang S, Tong S, Sun Y, Zhang L, Jiang T. Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling. Bioorg Med Chem. 2013;21:5012–20.View ArticlePubMedGoogle Scholar
  21. Qiu P, Dong P, Guan H, Li S, Ho CT, Pan MH, McClements DJ, Xiao H. Inhibitory effects of 5-hydroxy polymethoxyflavones on colon cancer cells. Mol Nutr Food Res. 2010;54:S244–52.View ArticlePubMedGoogle Scholar
  22. Hong CY, Huang SC, Lin SK, Lee JJ, Chueh LL, Lee CH, Lin JH, Hsiao M. Norcantharidin-induced post-G (2)/M apoptosis is dependent on wild-type p53 gene. Biochem Biophys Res Commun. 2000;276:278–85.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017